isononanoyl oxybenzene sulfonate
Sino Biopharm Acquires Merck’s PD-1xVEGF Bispecific Partner LaNova for up to $951M
Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal
Actionable Insights Powered by AI
Sino Biopharm; LaNova Medicines; acquisition; Merck; PD-1xVEGF bispecific antibody; cancer therapy; Chinese pharma; $951 million deal